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The Management of Primary Hyperparathyroidism
Michael Kleerel<oper, M D *

fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13, 1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents of the Proceedings can be found at the back of
this issue.

The surgical management of patients with primary hyperparathyroidism. S.A. Wells Jr and G.S. Leight (152)

I n the hands of a skilled parathyroid surgeon, parathyroidectomy (PTX) is a curative procedure for primary
hyperparathyroidism (PHPT) more than 95% of the time.
Why then do we need to discuss the management of
PHPT further? Why are not all patients whose diagnosis is
firmly established on clinical and biochemical grounds
sent to a skilled parathyroid surgeon for elective PTX?
The questions that remain are really philosophical: What
is meant by " c u r e " of PHPT? Which patients with PHPT
have a disease that needs a "cure"?

In the now-classic study conducted at the Mayo Clinic
(1), a large number of patients with asymptomatic PHPT
was followed prospectively up to 10 years after the initial
diagnosis. Twenty percent of the patients were lost to
f o l l o w - u p d u r i n g t h e observation period, and 20% of the
patients had progression of the disease so that PTX was
indicated. In retrospect, it was apparent that a substantial
number of patients in w h o m the disease was considered
to have progressed were initially misclassified and that
the rate of progressive disease may be less than that
which was observed. A defect in the study design was the
failure to assess the effect of successful PTX on the natural history of the disease. In addition, this study was
undertaken before sophisticated techniques for measuring bone mass (and the effect of PTH excess on bone
mass) were available. These problems were addressed by
two papers in this section of the Symposium.

Is parathyroidectomy of benefit in primary hyperparathyroidism? S. Posen, P. Clifton-Bligh, T.S. Reeve, C. Wagstaffe, and M . Wilkinson (154)
Medical approaches to the management of primary
hyperparathyroidism. J.P. Bilezikian (159)
fstrogen therapy for postmenopausal women with primary
hyperparathyroidism. R. Marcus, P. Madvig, M . Crim, J.
Kosek, and A. Pont (162)

During the past two decades, many patients with PHPT
have had the diagnosis considered because of a chance
finding of hypercalcemia on a biochemical screen, performed either as a routine measure in a well patient or as
a screening test ordered for other reasons in an ill
patient. Today, most patients with PHPT present in this
way, rather than as the more classic patient with "stones,
bones and abdominal groans."

Thefirst of these, by Posen and his colleagues (pp. 154ff.),
was a retrospective analysis of 128 cases which were
reviewed an average of 7.8 years after "successful" PTX.
This study provided some surprising and challenging
observations. Although 15% o f t h e patients had died dur-

Most consultants to w h o m patients with PHPT are referred
develop arbitrary criteria that mandate PTX at the time of
diagnosis. These include signs or symptoms directly referable to hypercalcemia, nephrolithiasis, skeletal disease, peptic ulcer disease, pancreatitis, or impaired renal
function. Most physicians have a limit point for hypercalcemia above which all patients are referred for PTX.
While this arbitrary criterion varies among physicians,
most accept a limit of 11.5 to 12.0 m g / d l .
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ing the follow-up period, death could be attributed to
surgery in only one case. Whether the death rate reflects
the fact that prevalence of PHPT increases with age or
whether PHPT contributed to irreversible deterioration
in function before surgery could not be ascertained from
this study. In contrast to other studies, PTX did not appear
to have an entirely protective effect against the development of nephrolithiasis. No patient w h o was free of
stones before PTX developed stones during the postoperative follow-up. However, in the 70% of patients w h o
had nephrolithiasis before surgery, no significant reduction occurred in the number of patients w h o developed
recurrent stones. Successful PTX did not havean appreciable effect on hypertension present in 40-50% of the
patients, nor did it restore impaired renal function. Using
crude radiographic assessment, the authors found no
improvement in the prevalence or degree of osteoporosis after PTX.

reports of increased prevalence of nonparathyroid malignancy in PHPT when compared to the general populat i o n , but it has never been clearly established whether
this is more than the chance occurrence of two relatively
c o m m o n conditions in an aging population. The observation by Posen, et al focuses attention on this potential
" c o m p l i c a t i o n " of PHPT. If hypercalcemia, elevated PTH
levels, or perhaps PHPT itself is in some way " m i t o genic," it is surprising that evidence for this fact was not
found in the 10-year prospective study at the Mayo
C! inic. The prevalence of malignancy in a separate group
of 74 patients w h o did not have surgery is not k n o w n but
would be of interest.
If successful PTX is without obvious benefit in patients
with mild PHPT, has anything new been learned since
the Mayo Clinic study of patients w h o were not operated? Neer and his colleagues reported their three-year
study of a small number of such patients. Like the Mayo
Clinic experience, the drop-out rate was relatively high
(12%), an occurrence which must be carefully considered whenever a decision to follow a patient with PHPT is
undertaken. During a three-year period, the Boston
group detected no significant progression o f t h e disease,
as evidenced by serum calcium and inorganic phosphate
levels, urine calcium excretion, renal function, and bone
mineral content. Several anecdotal reports exist of
patients with established mild PHPT w h o developed
sudden marked rises in serum calcium while under
observation. Since at present no way of predicting this
rare, life-threatening complication is k n o w n , every
attempt must be made to ensure continuous observation
of all patients with PHPT w h o do not undergo elective
PTX at the time of initial diagnosis.

Neer and his colleagues from the Massachusetts General
Hospital presented similar observations on 45 patients
followed prospectively for three years after successful
PTX. These patients all had mild, asymptomatic PHPT
before surgery. The decision to operate was based on the
presenceof impaired renal function or, more frequently,
on the presence of osteopenia (bone mineral content
more than two standard deviations below expected for
age, sex, and race). Two patients developed kidney
stones during the f o l l o w - u p period. As a group, there
was no improvement in blood pressure or in renal funct i o n , nor was there any restoration of the deficit in bone
mineral content. Perhaps of greater importance was the
failure of PTX to slow the rate of bone loss when the
group was considered as a w h o l e , although such deceleration was observed in some patients.

Wells and Leight (pp.152 ff.) described the type of surgery
required for patients with PHPT, highlighting their experiences at Duke University in North Carolina and Washington University in St. Louis. Most surgeons prefer to
identify all four parathyroid glands at the time of initial
neck exploration. The surgeon should rely on his or her
own skill at identifying parathyroid tissue and resect those
glands that appear macroscopically enlarged (>50 mg). At
the time of surgery, the role of the pathologist is to confirm that resected tissue is indeed parathyroid, and the
surgeon should not rely on the descriptive terms "parathyroid adenoma" and "parathyroid hyperplasia".

Posen, et al also reported findings in 32 patients w h o
were observed for an average of 6.6 years after unsuccessful neck exploration for PHPT. There were four
deaths in this group (12.5%), one of which resulted f r o m
progressive vertebral fractures and respiratory failure,
presumably a manifestation of progressive osteitis fibrosa.
As was the case with the successfully treated patients,
kidney stones did not occur in those patients w h o were
free of stones preoperatively. They found no other evidence for progression of PHPT.
A noteworthy and challenging observation was the
seemingly high prevalence of nonparathyroid malignancy in those patients w h o remained hypercalcemic
after surgery. In the successfully treated group, eight of
128 (6%) developed a variety of malignancies. However,
seven of the unsuccessfully treated group (22%) developed malignancy (p<0.01). There have been several

Of 350 patients observed over a five-year p e r i o d , 68%
had a single enlarged gland, 22% had two or three
enlarged glands, and 10% had four enlarged glands. During a four-year f o l l o w - u p , PHPT did not recur in any
patient with single gland enlargement and recurred in
only one patient with two or three gland enlargement.
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Patients with four gland enlargement have been managed by total parathyroidectomy and autotransplantation of tissue in the forearm muscle. The incidence of
graft failure was lessthan 5%. Of patients with f o u r g l a n d
enlargement, 36% had familial hyperparathyroidism.
The incidence of recurrent hypercalcemia in patients
with four gland enlargement without familial hyperparathyroidism was 15%.

the serum calcium may not be normalized by administration of estrogen, the rate of bone loss may be decreased.

Summary and Conclusions
If performed by a skilled parathyroid surgeon, elective
parathyroidectomy is a simple, safe, and effective means
of curing PHPT in more than 95% of cases. No equally
effective medical therapy exists for this disease, although
the administration of estrogens to postmenopausal
w o m e n with PHPT holds promise of decreasing the rate
of bone loss. Many patients, perhaps the majority, derive
no clinical benefit from having their disease " c u r e d " by
PTX. What is not currently available from the data, either
in the published literature or in the material presented at
this Symposium, is the means to predict accurately at the
time of diagnosis which patient is likely to develop c o m plications if not cured. To the classic list of "stones,
bones, and abdominal groans" that complicates PHPT
must be added a possible increased occurrence of n o n parathyroid malignancy in untreated patients. If close
observation during f o l l o w - u p after diagnosis can be
assured, only a small number of patients will develop
major complications (such as life-threatening hypercalcemia) if left untreated. Careful observation must
remain an important caveat, since two prospective studies have documented a 12% and 20% drop-out rate
during three and 10-year follow-up periods, respectively.

There remains a group of patients with PHPT in w h o m
elective surgery would normally be recommended, but
because of other medical considerations they are at too
great a risk for elective surgery. There is also a growing
group of patients for w h o m surgery is recommended but
w h o decline surgical intervention. Bilezikian (pp.159ff.)
f r o m Columbia University outlined medical alternatives
for these patients. General principles of management
include maintaining adequate hydration and avoiding
immobilization and thiazide diuretics. There is limited
evidence that restriction of dietary calcium is of benefit.
However, if one demonstrates increased intestinal absorption of calcium or elevated 1-25 dihydroxy cholecalciferol levels, dietary restriction of calcium might be
beneficial.
Drug therapy to inhibit parathyroid secretion (e.g., betaadrenergic-blockade and histamine receptor antagonists) or to inhibit the action of PTH on bone (e.g., estrogens, calcitonin, diphosphonates) has not been helpful
in most centers. However, scattered case reports exist of
a short-term reduction in serum calcium with some of
these drugs. Estrogens have the most potential benefit,
particularly in postmenopausal women with PHPT. While
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